Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MAINZ BIOMED B.V.

(MYNZ)
  Report
Delayed Nasdaq  -  03:56 2022-09-29 pm EDT
6.740 USD   -6.85%
09/29Mainz Biomed Stock Higher; Market Expansion Of Its Best-In-Class Cancer Diagnostics Power The Move ($MYNZ)
AQ
09/28Mainz Biomed B : Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and Financial Strategy - Form 6-K
PU
09/28Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mainz Biomed N.V. and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates

08/16/2022 | 03:01am EDT

Mainz Biomed N.V. and Dante Genomics announced the formal commencement of ColoAlert's consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz's product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets. With the ColoAlert test CE-IVD certified and patient collection kit CE marked to the latest IVDR requirements, ColoAlert will now be marketed through Dante's extensive database and sold via Dante's, region-specific, ecommerce websites.

Dante Genomics is a global leader in whole genome sequencing and holds an existing database of tens of thousands of whole genomes. The company has a product development and commercial franchise focused on providing preventive healthcare solutions. It achieves this by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals.


© S&P Capital IQ 2022
All news about MAINZ BIOMED B.V.
09/29Mainz Biomed Stock Higher; Market Expansion Of Its Best-In-Class Cancer Diagnostics Pow..
AQ
09/28Mainz Biomed B : Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, ..
PU
09/28Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and..
GL
09/28Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and..
AQ
09/27Mainz Biomed (nasdaq : MYNZ) could storm Wall Street with its molecular genetic diagnostic..
AQ
09/26Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer..
AQ
09/20Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board
GL
09/20Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board
AQ
09/20Mainz Biomed B.V. Appoints Dr. Douglas Rex to its Medical Advisory Board
CI
09/19Mainz Biomed B.V.(NasdaqCM:MYNZ) added to S&P Global BMI Inde..
CI
More news
Analyst Recommendations on MAINZ BIOMED B.V.
More recommendations
Financials (USD)
Sales 2022 0,70 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 97,6 M 97,6 M -
Capi. / Sales 2022 140x
Capi. / Sales 2023 17,6x
Nbr of Employees -
Free-Float 76,2%
Chart MAINZ BIOMED B.V.
Duration : Period :
Mainz Biomed B.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MAINZ BIOMED B.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 6,74 $
Average target price 25,00 $
Spread / Average Target 271%
Managers and Directors
Guido Baechler Chief Executive Officer & Director
William J. Caragol Chief Financial Officer
Hans Johan Hekland Independent Director
Nicole Holden Independent Director
Sector and Competitors